---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-25-000026"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:32:07.492089+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics Q3 net income $15.9M, Sephience launch revenue $19.6M

## Summary
- Total revenue $211.0M vs $196.8M YoY; net income $15.9M vs loss of $106.7M.
- Sephience launch: $19.6M revenue (US $14.4M, ex-US $5.2M), 521 start forms from 141 prescribers, 341 patients on therapy.
- DMD franchise revenue $85.9M (Translarna $50.7M, Emflaza $35.2M); Evrysdi royalties $70.8M.
- Full-year 2025 revenue guidance narrowed to $750-$800M; GAAP R&D/SG&A $805-$835M.
- Cash and marketable securities $1,687.8M as of Sep 30, 2025 (up from $1,139.7M at Dec 31, 2024).

## SEC filing metadata
- accession: 0001070081-25-000026
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008125000026/0001070081-25-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008125000026/tmb-20251104x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-25-000026
- JSON: https://secwatch.observer/filing/0001070081-25-000026.json
- Plain text: https://secwatch.observer/filing/0001070081-25-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.